对于患有BRCA1/2致病变体的健康妇女的决策指导 随机对照EDCP-BRCA试验的结果
Stephanie Stock1, Anna Isselhard, Arim Shukri
1Faculty of Medicine, University of Cologne and Institute for Health Economics and Clinical Epidemiology, Cologne; Faculty of Medicine, University of Cologne and Center for Familial Breast and Ovarian Cancer, University Hospital Cologne; Faculty of Medicine, University of Cologne and Institute for Health Economics and Clinical Epidemiology, Cologne; Institute for Public Health and Healthcare Research, University of Bremen; Institute for Human Genetics, University Hospital Heidelberg; Department of Obstetrics and Gynecology, Rechts der Isar Hospital Technical University of Munich; Schumpeter School of Business and Economics, Competence Center for Health Economics and Healthcare Research, University of Wuppertal; Department of Obstetrics and Gynecology, Carl Gustav Carus University Hospital, Dresden; Faculty of Medicine, University of Cologne and Center for Familial Breast and Ovarian Cancer, University Hospital Cologne; Institute for Health and Healthcare Science, Martin Luther University of Halle-Wittenberg, Halle (Saale); Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Kiel; Faculty of Medicine, University of Cologne and Department of Psychosomatics and Psychotherapy, University Hospital Cologne; Department of Psychosomatic Medicine, Robert Bosch Hospital, Stuttgart; Department of Obstetrics and Gynecology, University Hospital Würzburg.
一个决策指导计划帮助BRCA1/2致病变体 (PV) 的妇女在预防性护理决策中发挥更积极的作用. 虽然决策角色的一致性没有显著差异,但干预组表现出更高的满意度和知识.
科学领域:
- 遗传学 遗传学 是一个
- 预防医学 预防医学
- 决策科学 决策科学 决策科学
背景情况:
- 患有BRCA1/2致病变体 (PV) 的女性面临着关于预防选择的关键决策.
- 制定了一个决策指导 (DC) 计划,以帮助这些女性在决策过程中.
- 该计划的有效性是根据所需和实际决策角色之间的一致性来评估的.
研究的目的:
- 评估一项针对BRCA1/2病原变体 (PV) 的妇女的决策指导 (DC) 计划.
- 评估DC对首选和实际决策角色之间一致性的影响.
- 检查二次结果,包括积极的角色参与,满意度,决策冲突和知识.
主要方法:
- 这是一项随机对照试验,涉及6个德国中心的389名健康的BRCA1/2PV携带者 (25至60岁).
- 参与者被分配到接受护士主导DC的干预组 (IG) 或对照组 (CG).
- 结果在基线,12周 (T2) 和6个月 (T3) 测量使用问卷.
主要成果:
- 在12周后,IG和CG之间决策角色一致性没有显著差异 (p = 0.128).
- 两组女性都采取了比偏好的更积极的角色,在IG的比例高 (40%) 与CG (24.4%) 相比.
- 干预组的参与者报告说,他们的满意度更高,决策冲突更少,知识增加.
结论:
- 开发的决策指导计划有效地支持BRCA1/2PV携带者积极参与预防性护理决策.
- 该计划增强了患者参与和理解复杂的医疗保健选择.
- 进一步的研究可能会探索长期影响和推动积极参与的具体组成部分.
更多相关视频
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
相关概念视频
Cancer Prevention
Some...
Clinical Trials: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
